MedTrace Logo

Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD

NCT00448266 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-01-22

No results posted yet for this study

Summary

This phase II/III trial will investigate the ability of chemotherapy with 'Intensified Aklylating Agents (IAA) to achieve a high pathological complete response (pCR) rate when employed in the preoperative chemotherapy of breast cancer with evidence of a Homologous Recomination Deficiency (HRD).

Conditions

Interventions

DRUG

Intensified Cyclophophamide, Carboplatin and Thiotepa

2 courses of Intensified Cyclophophamide, Carboplatin and Thiotepa with PBPC support

DRUG

dose dense adriamycine and cyclophosphamide

dose dense adriamycine and cyclophosphamide, Q 2 weeks

Sponsors & Collaborators

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Sjoerd Rodenhuis · The Netherlands Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-02-28
Completion
2011-02-28

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00448266 on ClinicalTrials.gov